Three years of methotrexate and secukinumab: Outcomes of psoriatic arthritis in a real-life setting

J Am Acad Dermatol. 2022 Jan;86(1):241-243. doi: 10.1016/j.jaad.2021.02.004. Epub 2021 Feb 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antirheumatic Agents* / adverse effects
  • Arthritis, Psoriatic* / drug therapy
  • Humans
  • Methotrexate / adverse effects

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • secukinumab
  • Methotrexate